The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low dens...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Heart J
Hlavní autoři: Landlinger, Christine, Pouwer, Marianne G., Juno, Claudia, van der Hoorn, José W.A., Pieterman, Elsbet J., Jukema, J. Wouter, Staffler, Guenther, Princen, Hans M.G., Galabova, Gergana
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2017
Témata:
Basic Science
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5837708/
https://ncbi.nlm.nih.gov/pubmed/28637178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehx260
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky